Again CHMP ‘fails to recognize importance of’ obesity drug, awaits CV outcomes trial
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has stuck firm to an earlier decision, declining to recommend marketing authorization for Vivus' obesity treatment Qsiva (phentermine/topiramate ER) potentially pushing back EU development at least 2-3 years.